IPSC Stock Overview
A biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Century Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.85 |
| 52 Week High | US$5.51 |
| 52 Week Low | US$0.78 |
| Beta | 1.77 |
| 1 Month Change | -15.84% |
| 3 Month Change | -32.54% |
| 1 Year Change | -79.91% |
| 3 Year Change | -92.70% |
| 5 Year Change | n/a |
| Change since IPO | -96.28% |
Recent News & Updates
Recent updates
Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101
Jun 20Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely
Mar 06
Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy
Feb 01We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate
Oct 23Century Therapeutics receives IND clearance for allogeneic cell therapy candidate
Aug 25Shareholder Returns
| IPSC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.6% | 0.6% | -0.5% |
| 1Y | -79.9% | -3.8% | 24.3% |
Return vs Industry: IPSC underperformed the US Biotechs industry which returned -3.1% over the past year.
Return vs Market: IPSC underperformed the US Market which returned 25.2% over the past year.
Price Volatility
| IPSC volatility | |
|---|---|
| IPSC Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: IPSC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IPSC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 159 | Brent Pfeiffenberger | www.centurytx.com |
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors.
Century Therapeutics, Inc. Fundamentals Summary
| IPSC fundamental statistics | |
|---|---|
| Market cap | US$70.08m |
| Earnings (TTM) | -US$129.89m |
| Revenue (TTM) | US$2.68m |
26.9x
P/S Ratio-0.6x
P/E RatioIs IPSC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPSC income statement (TTM) | |
|---|---|
| Revenue | US$2.68m |
| Cost of Revenue | US$100.17m |
| Gross Profit | -US$97.48m |
| Other Expenses | US$32.41m |
| Earnings | -US$129.89m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.53 |
| Gross Margin | -3,631.93% |
| Net Profit Margin | -4,839.46% |
| Debt/Equity Ratio | 0% |
How did IPSC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 06:56 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Century Therapeutics, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Charlie Yang | BofA Global Research |
| William Maughan | Canaccord Genuity |